达格列净致溶血性贫血伴黄疸1例  

Dapagliflozin Induced Hemolytic Anemia with Jaundice:A Case Report

作　　者：王兰 何琳 边原[2] 王双梅[1] WANG Lan;HE Lin;BIAN Yuan;WANG Shuangmei(Department of Pharmacy,the People's Hospital of Jinniu District,Chengdu City,Chengdu 610036,China;Department of Pharmacy,Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital/Affiliated Hospital of University of Electronic Science and Technology,Chengdu 610072,China)

机构地区：[1]成都市金牛区人民医院西药剂科,成都610036 [2]四川省医学科学院·四川省人民医院,电子科技大学附属医院药学部,成都610072

出　　处：《医药导报》2025年第3期484-485,共2页Herald of Medicine

基　　金：四川省成都市金牛区医学会科研课题(JNKY 2024-41)。

摘　　要：1例69岁男性患者,因2型糖尿病给予达格列净片10 mg口服,qd,约7 d后出现溶血性贫血伴黄疸。该文通过回顾性分析该药物不良反应发生、诊疗及随访过程,对达格列净与药物不良反应的发生进行了关联性评价,结合相关文献分析了药物不良反应的可能机制。该例不良反应罕见,建议临床使用达格列净时加强对血液系统不良反应的监护。The patient,male,69-year-old,was given 10mg of dapagliflozin tablets qd for type 2 diabetes mellitus.He developed hemolytic anemia with jaundice about 7 days after oral administration.The occurrence,diagnosis,treatment and follow-up of the adverse drug reactions were retrospectively analyzed.The correlation between dapagliflozin and adverse drug reactions was evaluated,and the possible mechanism of the adverse drug reactions was discussed through literature analysis.This case of adverse drug reactions is rare.We suggested that the monitoring of the adverse reactions of blood system should be strengthened to ensure the safety of clinical use of dapagliflozin.

关 键 词：达格列净 溶血性贫血 黄疸 药品不良反应 

分 类 号：R977.1[医药卫生—药品] R969[医药卫生—药学]